Advertisement

Der Schmerz

, Volume 32, Issue 2, pp 131–138 | Cite as

Akutschmerztherapie bei Patienten mit Substanzabhängigkeitssyndrom

  • J. Quinlan
  • F. Cox
Pain Clinical Updates

In diesem Übersichtsbeitrag werden Patienten beschrieben, die illegale Opioide wie Heroin konsumieren, verordnete Opioide für die nichtmedizinische Nutzung abzweigen oder andere verbotene Substanzen einnehmen. Zu Letzteren zählen Stimulanzien (Amphetamine, Kokain), sedierende Substanzen (Alkohol, Barbiturate, Benzodiazepine) und weitere, wie etwa Cannabis, Meskalin und LSD.

Definitionen

Die Nomenklatur in Bezug auf illegalen Substanzkonsum bleibt unübersichtlich, in der Internationalen statistischen Klassifikation der Krankheiten und verwandter Gesundheitsprobleme (ICD-10, herausgegeben von der Weltgesundheitsorganisation 2016) wird aber „Abhängigkeitssyndrom“ als Begriff bevorzugt [ 32]. Andere Begriffe wie „Sucht“, „Substanzgebrauchsstörung“ und „Substanzmissbrauch“ beziehen sich auf dieselbe Störung, im Sinne der Eindeutigkeit und Einfachheit verwenden wir in diesem Übersichtsbeitrag jedoch „Abhängigkeitssyndrom“. Das Abhängigkeitssyndrom wird folgendermaßen definiert:

Eine...

Acute pain management in patients with drug dependence syndrome

Notes

Interessenkonflikt

J. Quinlan und F. Cox geben an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Alcohol and Drug Foundation (2017) Infographic: alcohol and drugs affect everyone. http://adf.org.au/wp-content/uploads/2017/02/infographic-alcohol-and-drugs-affect-everyone.pdf. Zugegriffen: 7. Apr. 2017Google Scholar
  2. 2.
    American Society of Addiction Medicine (2011) http://www.asam.org/quality-practice/definition-of-addiction. Zugegriffen: 7. Apr. 2017
  3. 3.
    Babalonis S, Walsh SL (2015) Warnings unheeded: the risks of co-prescribing opioids and benzodiazepines. Pain Clin Updat 23:1–7Google Scholar
  4. 4.
    Bounes V, Palmaro A, Lapeyre-Mestre M, Roussin A (2013) Long-term consequences of acute pain for patients undermethadone or buprenorphine maintenance treatment. Pain Physician 16:E739–E747PubMedGoogle Scholar
  5. 5.
    Callaly T, Trauer T, Munro L, Whelan G (2001) Prevalence of psychiatric disorder in a methadone maintenance population. Aust N Z J Psychiatry 35:601–605CrossRefPubMedGoogle Scholar
  6. 6.
    Center for Substance Abuse Research, University of Maryland (2016) Peyote/mescaline factsheet. http://www.cesar.umd.edu/cesar/drugs/peyote.pdf. Zugegriffen: 7. Apr. 2017Google Scholar
  7. 7.
    Chapman CR, Davis J, Donaldson GW, Naylor J, Winchester D (2011) Postoperative pain trajectories in chronic pain patients undergoing surgery: the effects of chronic opioid pharmacotherapy on acute pain. J Pain 12:1240–1246CrossRefPubMedGoogle Scholar
  8. 8.
    Chou R, Cruciani RA, Fiellin DA, Compton P, Farrar JT, Haigney MC, Inturrisi C, Knight JR, Otis-Green S, Marcus SM, Mehta D, Meyer MC, Portenoy R, Savage S, Strain E, Walsh S, Zeltzer L, American Pain Society, Heart Rhythm Society (2014) Methadone safety: a clinical practice guideline from the American Pain Society and College on problems of drug dependence, in collaboration with the Heart Rhythm Society. J Pain 15:321–337CrossRefPubMedGoogle Scholar
  9. 9.
    Department of Health (England) and the devolved administrations (2007) Drug misuse and dependence: UK guidelines on clinical management. Department of Health (England), the Scottish Government, Welsh Assembly Government and Northern Ireland Executive, LondonGoogle Scholar
  10. 10.
    Gulur P, Williams L, Chaudhary S, Koury K, Jaff M (2014) Opioid tolerance—a predictor of increased length of stay and higher readmission rates. Pain Physician 17:E503–E507PubMedGoogle Scholar
  11. 11.
    Hines S, Theodorou S, Williamson A, Fong D, Curry K (1998) Management of acute pain in methadone maintenance therapy in-patients. Drug Alcohol Rev 27:519–523CrossRefGoogle Scholar
  12. 12.
    Huxtable CA, Roberts LJ, Somogyi AA, MacIntyre PE (2011) Acute pain management in opioid-tolerant patients: a growing challenge. Anaesth Intensive Care 39:804–823PubMedGoogle Scholar
  13. 13.
    Kopf A (2010) Abdominal cancer, constipation and anorexia. In: Kopf A, Patel NB (Hrsg) IASP guide to pain management in low-resource settings. IASP, SeattleGoogle Scholar
  14. 14.
    Kork F, Neumann T, Spies C (2010) Perioperative management of patients with alcohol, tobacco and drug dependency. Curr Opin Anaesthesiol 23:384–390CrossRefPubMedGoogle Scholar
  15. 15.
    Kram B, Kram SJ, Sharpe ML, James ML, Kuchibhatia M, Shapiro ML (2017) Analgesia and sedation requirements in mechanically ventilated trauma patients with acute, preinjury use of cocaine and/or amphetamines. Anesth Analg 124:782–788CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Macintyre PE, Russell RA, Usher KA, Gaughwin M, Huxtable CA (2013) Pain relief and opioid requirements in the first 24 hours after surgery in patients taking buprenorphine and methadone opioid substitution therapy. Anaesth Intensive Care 41:222–230PubMedGoogle Scholar
  17. 17.
    Makdissi R, Stewart SH (2013) Care for hospitalized patients with unhealthy alcohol use: a narrative review. Addict Sci Clin Pract 8:11CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Moyer V, Preventive Services Task Force. (2013) Screening and behavioral counseling interventions in primary care to reduce alcohol misuse. Ann Intern Med 159:210–218PubMedGoogle Scholar
  19. 19.
    Mayo-Smith MF (1997) Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of addiction medicine working group on Pharmacological management of alcohol withdrawal. JAMA 278:144–151CrossRefPubMedGoogle Scholar
  20. 20.
    National Drug Intelligence Center (2008) LSD factsheet. https://www.justice.gov/archive/ndic/pubs4/4260/index.htm. Zugegriffen: 7. Apr. 2017Google Scholar
  21. 21.
    National Institute for Health and Care Excellence (2017) Alcohol-use disorders: diagnosis and management of physical complications clinical guideline [CG100]. https://www.nice.org.uk/guidance/cg100. Zugegriffen: 7. Apr. 2017Google Scholar
  22. 22.
    Schaeffer T (2012) Abuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics. J Med Toxicol 8:400–407CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Schug SA, Palmer GM, Scott DA, Halliwell R, Trinca J et al (2015) SE Working Group of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine. Acute pain management: Scientific evidence. 4th ed. Melbourne: Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine. http://fpm.anzca.edu.au/documents/apmse4_2015_final. Zugegriffen: 7. Apr. 2017Google Scholar
  24. 24.
    Shoptaw SJ, Kao U, Heinzerling K, Ling W (2009) Treatment for amphetamine withdrawal. Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.CD003021.pub2 Google Scholar
  25. 25.
    Srisurapanont M, Jarusuraisin N, Jittiwutikan J (1999) Amphetamine withdrawal: II. A placebo-controlled, randomised, double-blind study of amineptine treatment. Aust N Z J Psychiatry 33:94–98CrossRefPubMedGoogle Scholar
  26. 26.
    Substance Abuse and Mental Health and Mental Health Services Administration (2014) National survey on drug use and health. https://www.samhsa.gov/data/sites/default/files/NSDUHFRR1-2014/NSDUH-FRR1-2014.pdf. Zugegriffen: 7. Apr. 2017Google Scholar
  27. 27.
    Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM (1989) Assessment of alcohol withdrawal: the revised clinical Institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 84:1353–1357CrossRefPubMedGoogle Scholar
  28. 28.
    Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S (2016) A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (phila) 54:1–13CrossRefGoogle Scholar
  29. 29.
    United Nations Office on Drugs and Crimes (2016) World drug report 2016. https://www.unodc.org/unodc/en/frontpage/2016/June/number-of-drug-dependent-adults-up-for-first-time-in-six-years–now-at-29-million_-unodc-world-drug-report-2016.html. Zugegriffen: 7. Apr. 2017Google Scholar
  30. 30.
    Vadivelu N, Singh-Gill H, Kodumudi G, Kaye AJ, Urman RD, Kaye AD (2014) Practical guide to the management of acute and chronic pain in the presence of drug tolerance for the healthcare practitioner. Ochsner J 14:426–433PubMedPubMedCentralGoogle Scholar
  31. 31.
    Wesson DR, Ling W (2003) The clinical opiate withdrawal scale (COWS). J Psychoact Drugs 35:253–259CrossRefGoogle Scholar
  32. 32.
    World Health Organization (2016) International statistical classification of diseases and related health problems, 10th revision. http://apps.who.int/classifications/icd10/browse/2016/en. Zugegriffen: 7. Apr. 2017Google Scholar

Copyright information

© Deutsche Schmerzgesellschaft e.V. Published by Springer Medizin Verlag GmbH, ein Teil von Springer Nature - all rights reserved 2018

Authors and Affiliations

  1. 1.Anaesthesia and Pain Management and Lead for Pain Services, Oxford University Hospitals NHS Foundation TrustUniversity of OxfordOxfordGroßbritannien
  2. 2.Pain Management ServiceRoyal Brompton and Harefield NHS Foundation TrustLondonGroßbritannien

Personalised recommendations